Results 161 to 170 of about 28,689 (318)

Successful treatment of palmoplantar pustulosis with topical ruxolitinib

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Neda Cramer, Phoebe Wellmann, Michael P. Schön, Rotraut Mössner   +3 more
wiley   +1 more source

Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Optimal treatment for frontal fibrosing alopecia (FFA) remains contentious. An international expert panel agreed that highly/ultra‐potent topical steroids were the preferred first‐line topical therapy. Preferred systemic therapies were 5‐alpha reductase inhibitors, followed by hydroxychloroquine.
Nekma Meah, Jane Li, Dmitri Wall, Katherine York, Bevin Bhoyrul, Laita Bokhari, Lachlan Coulthard, Leila Asfour, Leonardo Spagnol Abraham, Daniel Asz‐Sigall, Wilma F. Bergfeld, Regina C. Betz, Ulrike Blume‐Peytavi, Valerie Callender, Vijaya Chitreddy, Andrea Combalia, George Cotsarelis, Brittany Craiglow, Rachita Dhurat, Ncoza Dlova, Jeff Donovan, Andrei Doroshkevich, Samantha Eisman, Paul Farrant, Aida Gadzhigoroeva, Jack Green, Ramon Grimalt, Matthew Harries, Maria Hordinsky, Alan D. Irvine, Victoria Jolliffe, Spartak Kaiumov, Brett King, Steven Kossard, Joyce Lee, Won‐Soo Lee, Nino Lortkipanidze, Amy McMichael, Natasha Atanaskova Mesinkovska, Andrew Messenger, Paradi Mirmirani, Elise Olsen, Seth J. Orlow, Yuliya Ovcharenko, Bianca Maria Piraccini, Rodrigo Pirmez, Adriana Rakowska, Pascal Reygagne, Janet Roberts, Lidia Rudnicka, David Saceda‐Corralo, Jerry Shapiro, Pooja Sharma, Tatiana Silyuk, Poonkiat Suchonwanit, Anita Takwale, Antonella Tosti, W. I. Visser, Sergio Vañó‐Galván, Annika Vogt, Martin Wade, Leona Yip, Abraham Zlotogorski, Cheng Zhou, Rodney Sinclair   +64 more
wiley   +1 more source

JAK-2 inhibitors and allogeneic transplant in myelofibrosis [PDF]

, 2015
7The activation of the JAK1/JAK2 pathway plays a crucial role in the pathogenesis of myelofibrosis. Treatment with the JAK2 inhibitor ruxolitinib demonstrated to reduce splenomegaly and symptoms in patients affected by myelofibrosis, leading to a ...
Cigana, C, De Marchi, R, Fanin, Renato, Lazzarotto, D, Patriarca, Francesca, Perali, G, Sperotto, A   +6 more
core  

Effects of inhibition of Janus kinase signalling during controlled mechanical ventilation on the rate of skeletal muscle protein synthesis

The Journal of Physiology, EarlyView.
Abstract figure legend 2H2O labelling was used to examine muscle protein fractional synthesis rates (FSR) in an intensive care unit (ICU) model and non‐anaesthetized control rats, and to compare the effects of a Janus kinase (JAK)/STAT inhibitor on protein FSR in the ICU model.
William J. Evans, Mahalakshmi Shankaran, Lars Larsson, Nicola Cacciani, Yvette Hedström, James L. Kirkland, Tamar Tchkonia, Hussein Mohammed, Tyler Field, Marc K. Hellerstein   +9 more
wiley   +1 more source

Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies

Dermatology and Therapy
Introduction Standard therapy for patients with mild to moderate atopic dermatitis (AD) typically includes topical therapies; however, patients with more extensive AD and/or AD refractory to topical therapy may benefit from systemic treatment ...
Eric L. Simpson, Leon Kircik, Andrew Blauvelt, Howard Kallender, Daniel Sturm, Mingyue Wang, Lawrence F. Eichenfield   +6 more
doaj   +1 more source

Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a dismal prognosis, largely because of late‐stage diagnosis and therapeutic resistance. PDAC incidence has been rising, with modifiable and non‐modifiable risk factors contributing to disease development.
Alessandro Mannucci, Ajay Goel
wiley   +1 more source

Real-World Evidence of Ruxolitinib In The Treatment of Myelofibrosis: Experince of A Portuguese Hospital Center [PDF]

, 2016
Anabela Almeida, K Alnajjar, Daniel Viriato   +2 more
openalex   +1 more source

Ruxolitinib and Severe COVID-19

Infection & Chemotherapy, 2021
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit   +1 more
openaire   +2 more sources

Ruxolitinib in a Pediatric Patient with Chronic Gvhd [PDF]

, 2017
Nicole Karras, Jae Yeon Jung, Jonathan Cotliar   +2 more
openalex   +1 more source

Early IL‐1 Inhibition in Still's Disease: A Window of Opportunity for Improving Outcomes

ACR Open Rheumatology, Volume 7, Issue 10, October 2025.
Objective Still's disease is a complex, multisystemic disorder requiring prompt diagnosis and treatment. This study provides a general assessment of a Still's disease cohort aiming to evaluate the efficacy of early intervention with interleukin‐1 inhibitors (IL‐1i) in achieving clinical inactive disease (CID) and reducing glucocorticoid use in patients
Sara Bindoli, Cristina Cadore, Irina Guidea, Andrea Doria, Roberta Ramonda, Paolo Sfriso   +5 more
wiley   +1 more source